Document |
Document Title |
WO/2023/086514A1 |
The present disclosure describes compounds of Formula (I) and pharmaceutically acceptable salts thereof.
|
WO/2023/080049A1 |
The purpose of the present invention is to provide a method for producing a high-quality fluorine-containing polyurethane without using an isocyanate, and to provide a fluorine-containing biscarbamate compound using said method. This pro...
|
WO/2023/080257A1 |
The method for producing isocyanate compounds comprises: a step (1) for obtaining an N-substituted carbamate compound by reacting a primary amine compound and a carbonate derivative, while removing by-product compounds that have a boilin...
|
WO/2023/080258A1 |
The present invention provides a carbonyl compound represented by general formula (I) (wherein R11 is an (n11+n12)-valent organic group, R12 is a monovalent organic group, n11 is an integer of 1-8, n12 is an integer of 0-7, and the sum o...
|
WO/2023/077236A1 |
A method for determining whether an individual with prediabetes, AMIS, type 2 diabetes, gestational diabetes, insulin resistance, or impaired glucose tolerance will respond to a bethanechol and N-acetylcysteine treatment is taught. Blood...
|
WO/2023/071328A1 |
Disclosed is a method for synthesizing 8-amino-1-{[2-(trimethylsilyl)ethoxy]methoxy}octane-3-one, which belongs to the technical field of pharmaceutical chemical synthesis. The method comprises the steps of: firstly, protecting diphenylm...
|
WO/2023/073606A1 |
The present invention relates to an industrially feasible and economically viable process for preparation of Edoxaban key intermediate viz. compound of formula (1) which is shown below:
|
WO/2023/072143A1 |
Disclosed in the present invention are a camptothecin derivative intermediate, and a preparation method therefor and the use thereof. The structural formula of the camptothecin derivative intermediate of the present invention is as shown...
|
WO/2023/077040A1 |
The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such ...
|
WO/2023/065610A1 |
The present invention relates to the field of drug synthesis. Disclosed is a preparation method for halofuginone intermediate trans-N-benzyloxycarbonyl-(3-hydroxy-2-piperidinyl)-2-aceton
e. The preparation method of the present invention...
|
WO/2023/064493A1 |
This invention provides compounds for the inhibition of papain-like proteases (PLpros) for the inhibition of viruses, including compounds of formula (I"), and pharmaceutically acceptable salts thereof.
|
WO/2023/019242A9 |
Provided herein are compounds and their pharmaceutically acceptable salts, lipid particles comprising such compounds or pharmaceutically acceptable salts thereof and compositions of the foregoing that can be used to reduce immune intoler...
|
WO/2023/056917A1 |
Provided herein are lipid compounds that can be used in combination with other lipid components, such as neutral lipids, cholesterol and polymer conjugated lipids, to form lipid nanoparticles for delivery of therapeutic agents (e.g., nuc...
|
WO/2023/055830A1 |
The present disclosure provides methadone prodrugs, pharmaceutical compositions, and their methods of use, where the pharmaceutical compositions comprise a methadone prodrug that provides enzymatically-controlled release of methadone, an...
|
WO/2023/050121A1 |
Disclosed in the present invention are biodegradable glass based on an amino acid, a peptide and a derivative, and a preparation method therefor and an application thereof. A main raw material of the glass is one of or a combination of a...
|
WO/2023/046882A1 |
There is provided herein compounds of formula I and pharmaceutically acceptable salts thereof, wherein X1, X2, Z, the ring containing Q1 to Q5, m and r have meanings as provided in the description. There is also provided medical uses of ...
|
WO/2023/044343A1 |
The present disclosure details various lipids, compositions, and/or methods of optimized systems and delivery vehicles for the delivery of nucleic acid sequences, polypeptides or peptides for use in vaccinating against infectious agents.
|
WO/2023/033015A1 |
Provided is a method for producing a Fmoc-protected amino group-containing compound, wherein a raw material amino group-containing compound is not wasted, by-production of Fmoc-β-Ala-OH is suppressed, and the purification of a target su...
|
WO/2023/035005A2 |
The present invention provides a dual inhibitor that inhibits histone deacetylase 6 (HDAC6) and heat shock protein 90 (HSP90) for amelioration and/or treatment of tumors through removal of immune suppression from tumor microenvironments ...
|
WO/2023/017474A1 |
This invention provides a flow synthesis process for producing sulfonylurea compounds of formula (1), including gliclazide, chlorpropamide and tolbutamide, and pharmaceutically acceptable salts thereof.
|
WO/2023/014160A1 |
The present invention relates to a crystalline form of a phenyl carbamate derivative compound and uses thereof, and more specifically, the present invention relates to a pattern 1 crystalline form, which is a thermodynamically more stabl...
|
WO/2023/014927A1 |
Disclosed herein are prodrugs of tapinarof and pharmaceutical formulations comprising tarpinarof, such as oral formulations. Further disclosed herein are methods for treating diseases and disorders of the gastrointestinal tract, skin, ey...
|
WO/2023/004687A1 |
Provided by the present invention is an unnatural amino acid, which is a compound having a structure as shown in formula (I) or an enantiomer thereof. Further provided by the present invention is an application of the unnatural amino aci...
|
WO/2023/004686A1 |
Provided is an unnatural amino acid, which is a compound having a structure as shown in formula (I) or an enantiomer thereof. Also provided is the use of the unnatural amino acid. Further provided is a recombinant protein containing the ...
|
WO/2023/001131A1 |
A preparation method for glufosinate-ammonium or a salt, an enantiomer or a mixture of enantiomers in all ratios thereof, the method being especially suitable for the preparation of glufosinate-ammonium, and greatly shortening steps in a...
|
WO/2023/001132A1 |
Provided is a method for preparing glufosinate or an analog thereof.
|
WO/2023/285545A1 |
The present invention relates to the field of polyurethane recycling and pertains to a method of recycling of a polyurethane, comprising a first alcoholysis step and a further thermolysis step. By means of the method according to the pre...
|
WO/2023/286053A1 |
The present invention pertains to a process for preparing of methyl chloroformyl[4-(trifluoromethoxy)phenyl]carbamate of formula I as intermediate in the preparation of arthropodicidal indoxacarb, comprising reaction of compound of formu...
|
WO/2023/285310A1 |
The invention relates to novel carbodiimides, to a process for the preparation and use thereof as a stabilizer in ester-based polyols, in polyethylene terephthalate (PET), in polybutylene terephthalate (PBT), in polytrimethylene terephth...
|
WO/2023/281040A1 |
The present invention relates to novel bi-functionalized trans-cyclooctenes of formula (I). It also relates to conjugates, compositions, medical uses of such compounds, and methods for producing such compounds as well as conjugates of su...
|
WO/2023/279205A1 |
The present technology relates to UV radiation-absorbing and/or visible radiation-absorbing compounds, and use of same in the preparation of compositions for protecting biological and nonbiological material against UV and/or visible radi...
|
WO/2023/277604A1 |
The present invention provides a novel compound for a capping layer, and an organic light-emitting device containing same.
|
WO/2022/266753A1 |
There are provided conjugates of Formula (V) wherein R1 is a triantennary targeting moiety comprising N-acetyl galactosamine and R2 is a bioactive agent which is preferably an oligonucleotide, as well as pharmaceutical compositions and m...
|
WO/2022/261752A1 |
There is currently no effective cure or treatment for neurodegenerative diseases associated with progranulin (PGRN) deficiency, such as frontotemporal dementia (FTD). FTD is a fast-progressing disease, with affected patients usually dyin...
|
WO/2022/263620A1 |
The present invention relates to a method for preparing a compound suitable for signal enhanced magnetic resonance imaging comprising the steps of vinylating a mono-, di- or tricarboxylic acid comprising a moiety -Q-Z with Q being O or N...
|
WO/2022/264168A1 |
The present invention provides a process for preparation of compound of formula (I), a key intermediate in synthesis of L-glufosinate or its salt. wherein P2 is an amino-protecting group; R1 is hydrogen, substituted or unsubstituted C 1 ...
|
WO/2022/265115A1 |
A method of producing a polypeptide compound, wherein a peptide compound represented by formula (P) is obtained by inducing an amide formation reaction between an amino-protected lactam compound represented by formula (R1) and an amino a...
|
WO/2022/247755A1 |
Provided herein are lipid compounds that can be used in combination with other lipid components, such as neutral lipids, cholesterol andpolymer conjugated lipids, to form lipid nanoparticles for delivery of therapeutic agents (e.g., nucl...
|
WO/2022/246929A1 |
The present invention relates to the technical field of drug synthesis, and provides a preparation method for an ABT-737 key intermediate and a preparation method for ABT-737. A compound having a structure as represented by formula I is ...
|
WO/2022/041171A9 |
The present application relates to a compound having the effects of being an antidepressant, narcotizing, alleviating pain, improving cognitive functions, protecting lungs, preventing or treating amyotrophic lateral sclerosis, or prevent...
|
WO/2022/240277A1 |
The invention relates to novel compounds of formulae (I) and (II), to the use thereof as a drug, particularly for the treatment of SARS-CoV-2, for the treatment of COVID-19 disease and any diseases related to beta-coronaviruses, and for ...
|
WO/2022/236270A1 |
A method for treating a subject in need thereof having a bone or blood cancer, or a cancer that metastasizes to bone that includes administering to the subject an effective amount of hydroxyureamethyl acylfulvene.
|
WO/2022/198116A9 |
Prodrugs of pharmacologically active 1,2,4-triaminobenzene derivatives of the General Formula (I); or pharmaceutically acceptable salts thereof, where the symbols R1, R2, R3, R4, R5 and R6a, R6b, and R6c and where the symbol Z are define...
|
WO/2022/213931A1 |
A prodrug of cannabidiol, a preparation method therefor, and a pharmaceutical composition thereof. The present invention further relates to a use of a compound or pharmaceutical composition containing the prodrug in preparation of drugs ...
|
WO/2022/213195A1 |
There is provided compounds of formula (I) or a pharmaceutically acceptable salt thereof, which are melatonin MT2 agonists, as well as pharmaceutical compositions comprising such compounds. The invention also provides the use of the comp...
|
WO/2022/201155A1 |
The present invention relates to a novel nitration process of 2- chloro -4- fluorobenzoic acid to 2-chloro-4- fluoro-5-nitrobenzoic acid, 2-chloro-4- f luoro-3 -nitrobenzoic acid and 3, 5-dinitro-2-chloro-4- fluorobenzoic acid; purifying...
|
WO/2022/202402A1 |
The present invention aims to provide: a production method for a semiconductor substrate that has excellent pattern rectangularity; and a composition for forming a resist underlayer film. The semiconductor substrate production method com...
|
WO/2022/198114A1 |
Prodrugs of pharmacologically active 1,2,4-triaminobenzene derivatives of the General Formula (I); or pharmaceutically acceptable salts thereof, where the symbols R1, R2, R3, R4, R5 and R6a, R6b, and R6c and where the symbol Z are define...
|
WO/2022/198115A1 |
Prodrugs of pharmacologically active 1,2,4-triaminobenzene derivatives of the General Formula (I); or pharmaceutically acceptable salts thereof, where the symbols R1, R2, R3, R4, R5 and R6a, R6b, and R6c and where the symbol Z are define...
|
WO/2022/190486A1 |
The present invention provides, as a novel compound that can be utilized for efficient synthesis or the like of a polypeptide comprising various amino acids, a silane-containing condensed cyclic dipeptide compound represented by formula ...
|